Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Evofem Biosciences ( (EVFM) ) has provided an announcement.
Evofem Biosciences has secured pivotal voting agreements from its Series E-1 stockholders and convertible noteholders to support its merger with Aditxt’s subsidiary, Adifem, under an amended merger agreement. This strategic move follows Aditxt’s substantial investment in Evofem, enabling the acquisition of SOLOSEC® and driving initiatives for Phexxi®. The merger aims to enhance Evofem’s growth trajectory, though it hinges on satisfying closing conditions including a significant capital raise by Aditxt.
See more insights into EVFM stock on TipRanks’ Stock Analysis page.